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S UMM A R Y
OB J E C T I V E : To identify the causes of symptoms sug-
gestive of tuberculosis (TB) among people living with
the human immunodeficiency virus (PLHIV) in South
Africa.
METHODS : A consecutive sample of HIV clinic attend-
ees with symptoms suggestive of TB (71 of cough,
weight loss, fever or night sweats) at enrolment and at 3
months, and negative initial TB investigations, were
systematically evaluated with standard protocols and
diagnoses assigned using standard criteria. TB was
‘confirmed’ if Mycobacterium tuberculosis was identi-
fied within 6 months of enrolment, and ‘clinical’ if
treatment started without microbiological confirmation.
R E SU LT S : Among 103 participants, 50/103 were pre-
antiretroviral therapy (ART) and 53/103 were on ART;
respectively 68% vs. 79% were female; the median age
was 35 vs. 45 years; the median CD4 count was 311 vs.
508 cells/mm3. Seventy-two (70%) had75% measured
weight loss and 50 (49%) had cough. The most common
final diagnoses were weight loss due to severe food
insecurity (n¼20, 19%), TB (n¼14, 14%: confirmed n
¼ 7; clinical n¼ 7), other respiratory tract infection (n¼
14, 14%) and post-TB lung disease (n ¼ 9, 9%). The
basis for TB diagnosis was imaging (n ¼ 7), bacterio-
logical confirmation from sputum (n ¼ 4), histology,
lumbar puncture and other (n¼ 1 each).
CONC LU S I ON : PLHIV with persistent TB symptoms
require further evaluation for TB using all available
modalities, and for food insecurity in those with weight
loss.
K E Y WORD S : South Africa; Xpertw MTB/RIF; TB
symptoms; human immunodeficiency virus
THEWORLDHEALTHORGANIZATION (WHO)
recommends regular screening of people living with
the human immunodeficiency virus (PLHIV) for
tuberculosis (TB) using a symptom screen comprising
any one of current self-reported cough, fever, weight
loss or night sweats (hereafter termed the ‘WHO
tool’), as an essential part of the HIV care package.1
Although people attending for HIV care in sub-
Saharan Africa are highly symptomatic,2 most of
those reporting WHO tool symptoms have negative
TB investigations,2–4 and a proportion continue to
report symptoms. Early identification of people with
active TB among PLHIV is a priority; however, the
evidence underpinning investigation pathways after
an initial sputum test is weak.5–14
The aim of our study was to determine the causes of
persistent or recurrent symptoms suggestive of TB
among ambulatory adults attending for HIV care
who had negative initial TB investigations.
METHODS
This sub-study was part of a prospective cohort study
evaluating a risk-based algorithm to prioritise Xpertw
MTB/RIF (Cepheid, Sunnyvale, CA, USA) testing
among adults attending for routine HIV care in South
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Africa: ‘Xpert for people attending HIV/AIDS care:
test or review?’ (XPHACTOR).15
XPHACTOR study population, recruitment and
procedures
XPHACTOR study flow, procedures and algorithm
are described in detail in the Online Appendix*
(section on ‘Main study procedures’, Appendix
Figure A.1). Briefly, we enrolled a systematic sample
(using a predetermined system designed to minimise
the risk of researcher selection bias) of adults (aged
718 years) attending four HIV clinics in Gauteng
Province, South Africa, irrespective of the presence of
symptoms suggestive of TB. Patients taking anti-
tuberculosis treatment within the previous 3 months
were excluded. Patients were enrolled into ‘on
antiretroviral therapy (ART)’ ‘ART-experienced’
and ‘pre-ART’ (in HIV care or newly diagnosed
HIV-positive, not taking ART) groups. At the time of
the study, ART eligibility comprised CD4 count
6350 cells/mm3 or WHO clinical stage 73. Re-
search staff screened participants for TB at monthly
intervals up to 3 months using a standardised
questionnaire that incorporated the WHO tool. The
study algorithm defined individuals as a priori at
highest risk of active TB if they had any of the
following: current cough, fever 7 3 weeks, night
sweats7 4 weeks, body mass index (BMI),18.5 kg/
m2, CD4 count ,100 cells/mm3 or weight loss
710%. A spot sputum sample was collected from
these individuals if possible for Xpert testing. At the
3-month visit, all participants underwent sputum
(induced if necessary) and blood cultures for myco-
bacteria (BACTEC MGITe 960e and 9240e sys-
tems; BD, Sparks, MD, USA). We allowed a broad
window period around the 3-month XPHACTOR
main study visit until around 6 months to maximise
follow-up.
Sub-study eligibility and enrolment
Between October 2013 and April 2014 at the
XPHACTOR 3-month visit, consecutive participants
who were not on anti-tuberculosis treatment and who
had persistent or recurrent symptoms suggestive of
TB were invited to participate in this sub-study.
Persistent or recurrent TB symptoms were defined as
1) self-report of any of cough, fever or night sweats at
enrolment, and self-report of any of the aforemen-
tioned symptoms at 3-month visit; or 2) self-report of
unintentional weight loss and75%measured weight
loss since XPHACTOR enrolment.
Figure 1 shows the sub-study flow and procedures.
A chest radiograph (CXR) was requested if there was
no film available for the previous 6 weeks, and all
were asked to bring samples (stool, early-morning
urine and sputum) for mycobacterial culture when
they attended for research physician assessment.
Further procedures were determined by symptoms
(Figure 1); if cough was reported, the research nurse
collected an additional sputum sample for bacterial
culture (induced if necessary), two nasopharyngeal
swabs and one oropharyngeal swab. Sputum samples
were tested using routine bacterial microscopy and
culture, and polymerase chain reaction (PCR) for
bacteria, including Bordetella pertussis. One naso-
pharyngeal swab was inserted directly into Regan
Lowe transport media for Bordetella spp. culture,
and the remaining swabs were placed in Primestore
medium for PCR detection of B. pertussis and other
pathogens (Figure 1). All samples were transported
within 24 h of collection to the research laboratory.
PCR for B. pertussis was performed in accordance
with the method described by Tatti et al.16 An
abdominal ultrasound scan was requested for those
with weight loss. Participants reporting fever or night
sweats were given a digital thermometer to record
oral temperature (morning, evening, and if any fever
or sweats) for 1 week.
Research physician assessment
Around 1 week after enrolment, sub-study partici-
pants underwent systematic clinical evaluation, in-
cluding examination by a research physician who
arranged a standard set of investigations according to
the participant’s symptoms (Figure 1 and Appendix
Figure A.2, Appendix section on ‘Sub-study research
physician assessment’).
First-line evaluation for cough was spirometry if
cough 78 weeks or features suggestive of chronic
obstructive pulmonary disease (COPD) or asthma; if
clinically appropriate, blood samples were collected
for C-reactive protein (CRP) testing to help distin-
guish the likelihood of bacterial infection and, if
cardiac failure was suspected, for serum b-natriuretic
peptide.
Second-line evaluation for cough comprised a trial
of appropriate treatment for those with clinical
features suggestive of cough due to upper airways
disease, angiotensin-converting enzyme (ACE) inhib-
itors or gastro-oesophageal reflux disease (GORD).
All participants were screened using validated tools
for depression (Patient Health Questionnaire 9
[PHQ-9]),17 household food insecurity (household
food insecurity access score [HFIAS]),18 and alcohol
misuse (Fast Alcohol Screening Test [FAST] score),19
and were asked about use of tobacco, snuff and
wood-burning stoves. Using a standardised form, the
physician abstracted information from clinic records
relevant to assigning final diagnoses, such as chronic
disease diagnoses, results of recent investigations in
particular for TB, and history of HIV, ART and TB.
*The appendix is available in the online version of this article, at
http://www.ingentaconnect.com/content/iuatld/ijtld/2019/
00000023/00000002/art000 .....
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Sub-study follow-up
Sub-study participants were followed for a further 3
months and screened for TB at each visit by research
staff using a standardised questionnaire incorporat-
ing the WHO tool, with further investigation for TB
in accordance with the XPHACTOR study algorithm
(Figure 1). The research physician reviewed partici-
pants at these visits if required to assign final
diagnoses.
Definitions
Final diagnoses were assigned by the research
Figure 1 Sub-study procedures. * Eligible if not on anti-tuberculosis treatment and persistent or
recurrent TB symptoms, defined as: 1) any of cough, fever, or night sweats at enrolment and 3-
month visit; or 2)75% measured weight loss at 3-month visit and reported unintentional weight
loss. † Sputum samples underwent macroscopic and microscopic evaluation; culture on 5% horse
blood agar (routine respiratory pathogens), Regan Lowe (Bordetella spp.), buffered charcoal yeast
extract (Legionella spp.); PCR for Bordetella spp.,M. pneumoniae, C. pneumoniae and Legionella
spp. ‡ PCR for Bordetella spp.,M. pneumoniae, C. pneumoniae and Legionella spp. § Aerobic and
anaerobic bacterial cultures. ¶ High priority (any of current cough, fever7 3 weeks, night sweats
7 4 weeks, body mass index , 18.5 kg/m2, CD4 , 1003106/l, measured weight loss7 10% in
preceding 6 months, or other feature raising high clinical suspicion of TB); medium priority (any of
fever , 3 weeks, night sweats, 4 weeks, measured weight loss, 10% in preceding 6 months);
low priority¼ no TB symptoms. XPHACTOR¼ Xpert for people attending HIV/AIDS care: test or
review? TB¼ tuberculosis; PCR polymerase chain reaction; FBC¼ full blood count; LRTI¼ lower
respiratory tract infection; CRP ¼ C-reactive protein; COPD ¼ chronic obstructive pulmonary
disease; HbA1c¼glycated haemoglobin; MC&S¼microscopy, culture and sensitivities; FNA¼ fine-
needle aspiration; HIV ¼ human immunodeficiency virus; AIDS ¼ acquired immune-deficiency
syndrome.
Causes of TB symptoms in HIV-positive adults 159
physician using pre-set criteria (Appendix Table A),
including the case definitions for TB detailed below.
TB case definitions
‘Confirmed’ TB was defined as a positive result on 1)
Xpert (on sputum sample), 2) line-probe assay (LPA)
performed on smear-positive or cultured isolate
(GenoType MTBDRplus, Hain Lifesciences, Nehren,
Germany) or 3) M. tuberculosis culture, from any
sample collected within 6 months of sub-study
enrolment. ‘Clinical TB’ was defined as anti-tubercu-
losis treatment started within 6 months of sub-study
enrolment in the absence of microbiological confir-
mation.
Radiological definitions
‘Probable radiological TB’ was defined as the
presence of 1) any of cavitation, predominantly upper
lobe infiltrates, pleural or pericardial effusion, or
clear miliary picture on CXR, or 2) any of abdominal
lymphadenopathy, splenic microabscesses, pleural or
pericardial effusion on ultrasound scan. ‘Possible
radiological TB’ was defined as the presence of any of
lymphadenopathy (hilar or mediastinal), pulmonary
nodules or other infiltrates. Participants with ‘prob-
able’ or ‘possible’ radiological TB features but
without bacteriological confirmation who started
anti-tuberculosis treatment within 6 months of sub-
study enrolment were assigned ‘clinical’ TB.
Ethical approval
The study protocol was approved by the ethics
committees of the University of the Witwatersrand,
Johannesburg; University of Cape Town, Cape Town,
South Africa; and the London School of Hygiene &
Tropical Medicine, London, UK. All participants
provided written informed consent or, if unable to
write, witnessed verbal consent.
RESULTS
Sub-study enrolment and eligibility
A total of 1147 XPHACTOR study participants were
screened for the sub-study, 45 of whom were
excluded because they were currently taking anti-
tuberculosis treatment (Figure 2). One further partic-
ipant was excluded because a stored sputum sample
collected for the main study was Xpert-positive when
tested after the 3-month visit. Among the remaining
1101 participants, 118 (11%) were eligible, and 103/
118 (87%) underwent physician assessment (53/103
[51%] on ART, 50/103 [49%] pre-ART), at a median
of 126 days (interquartile range [IQR] 96–175) after
enrolment in the parent study. Among 15/118 (13%)
participants who did not undergo physician assess-
ment (10 pre-ART, 5 on ART), all had only one
symptom (11/15 [73%]75% measured weight loss,
4/15 [27%] cough), and two subsequently had M.
tuberculosis isolated from the 3-month sputum
sample.
Participant characteristics
Table 1 presents the participants’ characteristics; 30/
50 (60%) pre-ART participants initiated ART during
study follow-up, and in the on-ART group, 28/51
(55%) were virologically suppressed. Overall, 40/102
(39%) had PHQ-9 scores suggestive of moderate
depression and 53/103 (51%) had HFIAS scores
indicating households with severe food insecurity.
The most common WHO tool symptoms reported
were weight loss (83/103, 81%), with 72/103 (70%)
having 75% measured weight loss and cough (50/
103, 49%); 57/103 (55%) had one WHO tool
symptom (45 [44%] weight loss, 9 [9%] cough, 3
[3%] night sweats), and 46/103 (45%) had multiple
symptoms (25 [24%] had two, 18 [17%] three, 3
[3%] four symptoms). Among participants reporting
cough, 20/50 (40%) had previously received anti-
tuberculosis treatment at a median of 4 years (IQR 2–
6) before sub-study enrolment (7/50 [14%] more than
one course), 29/50 (58%) were current or ex-smokers
Figure 2 Study flow. * Persistent TB symptoms, defined as: 1)
self-report of any of cough, fever, or night sweats at enrolment
and at 3-month visit; or 2) self-report of unintentional weight
loss and 75% measured weight loss. † 60/540 (11%) pre-ART
and 58/561 (10%) on ART/eligible. ‡ Pre-ART (n¼10); on ART (n
¼ 5). § No time (n ¼ 12); too unwell (n ¼ 1). ¶ Both pre-ART:
started anti-tuberculosis treatment before assessment (n ¼ 1);
died before assessment (n¼ 1). ** Confirmed: Xpertþ or LPAþ
from smear-positive/cultured isolate OR culture þ M. tubercu-
losis from any sample collected within 6 months from enrolment
to sub-study. ††Clinical: started treatment in the absence of
microbiological confirmation within 6 months from enrolment
to sub-study. ART ¼ antiretroviral therapy; þ ¼ positive; TB ¼
tuberculosis; LPA¼ line-probe assay.
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(7 [14%] had .15 pack years), 8/50 (16%) used
snuff, 5/50 (10%) used paraffin stoves and none used
wood-burning stoves. A further 18/50 (35%) report-
ed wheeze and 26/50 (52%) dyspnoea.
Among 72 participants with 75% measured
weight loss, the median BMI, weight loss and
percentage weight loss at physician assessment were
respectively 23 kg/m2 (IQR 18.9–25.9), 4.4 kg (IQR
3.6–6) and 6.8% (IQR 5.5–9.4). Of these 72 patients,
32 (50%) had HFIAS scores indicating severely food
insecure households, 29/71 (41%) had PHQ-9 scores
suggestive of moderate depression and 53/72 (74%)
had a monthly household income of ,2000 South
African rand; 67/72 (93%) had follow-up weight
measurements, among whom 42/67 (63%) gained
weight and in 12/67 (18%) weight was stabilised.
Among the 42 participants who gained weight during
follow-up, 16/42 (38%) had initiated ART, three of
whom had also started anti-tuberculosis treatment.
Among 36 participants reporting fever or night
sweats, 3/36 (8%) had measured fever .38.38C at
physician assessment or from home measurement.
Final diagnoses
Table 2 summarises the final diagnoses assigned over
a median of 100 days (IQR 89–144) of follow-up. For
nine participants (measured weight loss only, n ¼ 8;
measured weight loss and night sweats, n ¼ 1), we
were unable to determine any final diagnosis; these
patients were assigned a final diagnosis of ‘unex-
plained’ or ‘unexplained—symptom resolved sponta-
neously’. One hundred and twenty-one diagnoses
were assigned for the remaining 94/103 (91%)
participants. The most common diagnoses were
Table 1 Characteristics of study participants
Characteristic
Pre-ART
(n ¼ 50)
n (%)
On ART
(n ¼ 53)
n (%)
Total
(n ¼ 103)
n (%)
Demographics
Age, years, median [IQR] 35 [28–41] 45 [39–49] 40 [31–46]
Female 34 (68) 42 (79.3) 76 (73.8)
Black African 50 (100) 49 (92.5) 99 (96.1)
Completed secondary education (grade 12) 15 (30.0) 11 (20.8) 26 (25.2)
Number of people in household, median [IQR] 4 [3–5] 4 [2–5] 4 [2–5]
Monthly household income ,2000 ZAR 29 (58.0) 30 (56.6) 59 (57.3)
HIV-TB history
Duration since HIV diagnosed, months, median [IQR] 6 [4–17] 88 [52–118] 38 [6–99]
ART commenced after enrolment into main study* 25 (50.0) NA 25 (24.3)
Duration on ART, months, median [IQR] 3 [2–4]
(n ¼ 21)
76 [43–100] 47 [5–88]
(n ¼ 74)
Previous anti-tuberculosis treatment 4 (8.0) 29 (54.7) 33 (32.0)
.1 previous episode of anti-tuberculosis treatment 0 11 (20.8) 11 (10.7)
CD4†/viral load†/BMI
CD4, cells/mm3, median [IQR] 311 [162–445]
(n ¼ 49)
508 [354–673] 401 [226–588]
(n ¼ 102)
Viral load suppressed (,20 copies/ml) NA 28 (54.9)
(n ¼ 51)
29 (53.7)
(n ¼ 54)
BMI at enrolment to sub-study, kg/m2, median [IQR] 22.7 [19.3–26.0] 23.6 [19.6–26.1] 23 [19.4–26.1]
WHO tool symptoms reported
Unintentional weight loss‡ 75% 42 (84.0) 30 (56.6) 72 (69.9)
Cough 15 (30.0) 35 (66.0) 50 (48.5)
Night sweats 10 (20.0) 19 (35.9) 29 (28.2)
Fever 4 (8.0) 18 (34.0) 22 (21.4)
.1 of the above symptoms 17 (34.0) 29 (54.7) 46 (44.7)
Screening for food insecurity and depression
HFIAS score: severe food insecurity 23 (46.0) 30 (56.6) 53 (51.5)
HFIAS score: moderate food insecurity 11 (22.0) 8 (15.1) 19 (18.5)
PHQ-9 score 710 (moderate depression) 18 (36.0) 22 (42.3)
(n ¼ 52)
40 (39.2)
(n ¼ 102)
Tobacco/alcohol/drug use§
Ex- or current smoker 19 (38.0) 26 (49.1) 45 (43.7)
.15 pack years cigarette smoking 3/19 (15.8) 6/26 (23.1) 9/45 (20.0)
Current snuff user 7 (14.0) 15 (28.3) 22 (21.4)
Current harmful alcohol intake (FAST score 73) 9 (18.0) 7 (13.2) 16 (15.5)
Recreational drug use 0
(n ¼ 49)
2 (3.8) 2 (2.0)
*A further 5 pre-ART participants initiated ART following clinician assessment.
†Most recent of any result available within 1 year before, or within 6 weeks following clinician assessment.
‡75% measured weight loss and reported unintentional weight loss at sub-study enrolment.
§ ‘Current’ defined as use within past 1 year, and ‘smoker’ defined as having ever smoked 7100 cigarettes.
ART ¼ antiretroviral therapy; IQR ¼ interquartile range; ZAR ¼ South African rand; HIV ¼ human immunodeficiency virus; TB ¼ tuberculosis; NA ¼ not
applicable; BMI¼ body mass index; WHO¼World Health Organization; HFIAS¼Household Food Insecurity Access Score; PHQ-9¼ Patient Health Questionnaire 9;
FAST¼ Fast Alcohol Screening Test.
Causes of TB symptoms in HIV-positive adults 161
weight loss due to severe food insecurity (20/103,
19%), TB (14, 14%), upper respiratory tract infec-
tion (12, 12%) and post-TB chronic lung disease (9,
9%).
Table 3 summarises the final diagnoses for the most
common symptoms reported: cough and 75%
measured weight loss. Among 50 participants report-
ing cough, the most common diagnoses were upper or
lower respiratory tract infection (11/50, 22%), post-
tuberculous chronic lung disease (9/50, 18%), TB (7/
50, 14%: pulmonary only, n ¼ 4; extra-pulmonary
only, n¼1; both, n¼ 2), asthma (7/50, 14%), COPD
(5/50, 10%) and upper airways cough syndrome (4/
50, 8%). Samples collected from 40 participants for
respiratory pathogens yielded only one positive
sample that was PCR-positive for B. pertussis.
Among the 72 participants with measured weight
loss, the most common diagnoses were weight loss
due to severe food insecurity (20/72, 28%), TB (10/
72, 14%: pulmonary only, n ¼ 3; extra-pulmonary
only, n¼4; both, n¼3) and prolonged loss of appetite
(8/72, 11%: 4 due to medical treatment and 4 stress-
related). The most common diagnosis among 45
participants with weight loss in the absence of other
symptoms was severe food insecurity (13/45, 29%).
Of the 72 patients, 11 (15%) had weight loss
unexplained by study investigations, among whom
four gained weight after ART initiation. Nine of 68
participants (13%) with available samples had
glycated haemoglobin 7 6.5%; in two of these
weight loss was attributed to newly diagnosed type 2
diabetes mellitus. Thyroid function test abnormalities
were newly identified in 18/67 (27%); one participant
with biochemically subclinical hyperthyroidism (high
thyroxine, normal thyroid stimulating hormone) and
marked weight loss (18 kg) also had severe food
insecurity. Abdominal ultrasound scans were abnor-
mal for 22/65 (34%), five of whom had features
compatible with probable radiological TB and 17
other abnormalities (gallstones, n¼ 5; hepatomegaly,
n¼ 4; echogenic kidney or liver, n¼ 3; splenomegaly,
n¼ 2; metastatic disease, n¼ 2; fatty liver, n¼ 1).
Tuberculosis diagnoses
Appendix Figure A.2 gives the results of the
mycobacteriology and radiology requested for all
sub-study participants. All participants had at least
one sample subjected to mycobacterial culture;
culture was positive for M. tuberculosis in 5/103
(5%) participants (5/176, 3% sputum samples [one
multidrug-resistant]; 0/103 blood, 0/83 urine and 0/
57 stool). Of 98 CXRs, 17 (17%) fulfilled the criteria
for radiological TB (probable radiological TB, n¼12;
possible radiological TB, n ¼ 5); 6/17 (35%)
participants whose CXRs fulfilled the criteria for
radiological TB also fulfilled TB case definitions (3
confirmed, 3 clinical). Of 65 abdominal ultrasound
scans, 7 (11%) fulfilled the criteria for probable
radiological TB (abdominal only, n ¼ 4; abdominal
and possible renal, n ¼ 1; pericardial effusion and
abdominal, n ¼ 1; pleural and pericardial effusions
and abdominal TB, n ¼ 1); 6/7 (86%) participants
Table 2 Final diagnoses of patients*
Final diagnoses assigned
(n ¼ 103)
n (%)
Weight loss due to severe food insecurity 20 (19.4)
TB 14 (13.6)
Confirmed 7 (6.8)
Clinical 7 (6.8)
Upper respiratory tract infection 12 (11.7)
Post-TB chronic lung disease 9 (8.7)
Bronchiectasis 2 (1.9)
Chronic loculated pleural effusion 1 (1.0)
Likely 6 (5.8)
Weight loss due to loss of appetite 9 (8.7)
Treatment-related† 4 (3.9)
Stress-related 4 (3.9)
Unexplained 1 (1.0)
Asthma 7 (6.8)
Confirmed 2 (1.9)
Likely 5 (4.9)
COPD‡ 5 (4.9)
Confirmed 3 (2.1)
Likely 2 (1.9)
Weight loss due to depression 4 (3.9)
Upper airway cough syndrome 4 (3.9)
Confirmed 3 (2.9)
Likely 1 (1.0)
Perimenopausal vasomotor symptoms 4 (3.9)
Diarrhoeal illness§ 4 (3.9)
Other infection¶ 4 (3.9)
Malignancy# 3 (2.9)
Alcohol misuse** 3 (2.9)
Lower respiratory tract infection 2 (1.9)
Pertussis 2 (1.9)
Confirmed 1 (1.0)
Likely 1 (1.0)
Weight loss due to previously undiagnosed type 2 diabetes 2 (1.9)
Weight loss due to end-stage renal disease 2 (1.9)
Other†† 11 (10.7)
Unexplained 10 (9.7)
Unexplained - symptom resolved spontaneously 9 (8.7)
* 140 diagnoses were assigned for 103 participants: 70 (68%) had one final
diagnosis, 29 (28%) two diagnoses and 4 (4%) had three diagnoses.
† Attributed to new ART regimen (n¼2), radiotherapy for Kaposi’s sarcoma (n
¼ 1), dental extraction (n¼ 1).
‡One participant with likely COPD had a previous addiction to nyaope (a
street drug that is smoked and reported to contain heroin, cannabis and
antiretrovirals); one participant with confirmed COPD had clinical cor
pulmonale.
§Microbiological confirmation of isospora (n¼ 1), giardia (n¼ 1); cause not
known (n¼ 2).
¶ Escherichia coli urinary tract infection (n¼ 2), chronic skin infection (n¼ 1),
likely chronic pelvic infection (n¼ 1).
# Newly diagnosed Hodgkin’s lymphoma (n ¼ 1), progression of previously
diagnosed malignancy (renal cell carcinoma, n¼ 1; cervical cancer, n¼ 1).
**Hazardous alcohol intake and weight loss after stopping (n¼ 1), no other
cause identified for night sweats (n¼ 2).
†† Diagnoses for cough, n¼5 (ACE inhibitor-related, n¼1; GORD-related, n¼
1; post-thoracic surgery for benign lung mass, n¼ 1; post-infectious, n¼ 1;
smoking-related, n ¼ 1). Diagnoses for weight loss, n ¼ 6 (endoscopy-
confirmed gastritis, n¼1; recurrent small bowel obstruction, n¼1; confirmed
heart failure, n¼1; subclinical hyperthyroidism, n¼1; increased exercise, n¼
1; chronic unexplained gastrointestinal symptoms resolved by end of study, n
¼ 1).
TB ¼ tuberculosis; COPD ¼ chronic obstructive pulmonary disease; ART ¼
antiretroviral therapy; ACE ¼ angiotensin-converting enzyme; GORD ¼
gastroesophageal reflux disease.
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whose abdominal ultrasound scans fulfilled the
criteria for radiological TB also fulfilled TB case
definitions (3 confirmed, 3 clinical).
Of 103 sub-study participants, 14 (14%) (6 on
ART, 8 pre-ART) fulfilled TB case definitions (7
confirmed, 7 clinical). Eight participants started
treatment due to compatible imaging (4 ultrasound,
2 abdominal ultrasound and CXR, and 2 CXR), of
whom 3 were subsequently bacteriologically con-
firmed on sputum (1 Xpertþ culture, 2 culture). Four
participants started anti-tuberculosis treatment based
on a positive sputum result (2 Xpert, 2 culture). One
participant started treatment based on histology
following fine-needle lymph node aspiration, and
one based on lumbar puncture.
The median time from enrolment to start of anti-
tuberculosis treatment was 21 days (range 1–137) for
13 participants with a documented anti-tuberculosis
treatment start date. One further participant had
positive Xpert on sputum 149 days after enrolment
but an unknown treatment start date. Among the 8
pre-ART participants, 4 started anti-tuberculosis
treatment after ART initiation (3 within 3 months,
1 within 6 months). A further two participants who
were enrolled but who did not undergo physician
assessment fulfilled case definitions for confirmed TB,
of whom one died before anti-tuberculosis treatment
was initiated (Figure 2).
DISCUSSION
In this representative sample of HIV clinic attendees
in South Africa reporting persistent or recurrent
WHO tool symptoms 3 months after a negative
initial investigation for TB, among those able to
produce sputum, 14/103 (14%) had TB. Half started
anti-tuberculosis treatment based on imaging, mainly
abdominal ultrasound, which illustrated the limita-
tions of sputum-based diagnostics for detecting extra-
pulmonary TB. With an estimated 40% shortfall
globally between notified cases and estimated inci-
dence of TB in 2016, and with South Africa one of the
10 countries accounting for most of this gap,20 we
recommend using multiple diagnostic modalities,
particularly imaging, to help identify these missing
TB patients.
Our study is the first to systemically evaluate
patients established in HIV care with persistent or
recurrent symptoms suggestive of TB, and with an
initial negative Xpert result among those able to
produce sputum, for a broad spectrum of diagnoses.
Previous studies have investigated patients with
persistent symptom(s) for specific infectious5,7 or
non-communicable causes,6,8,14 or evaluated chronic
cough in smear-negative patients before the roll-out
of Xpert.9,12 Munyati et al. evaluated primary care
attendees in Zimbabwe with chronic cough and,
unsurprisingly, among 454 newly diagnosed HIV-
positive patients, the majority of the diagnoses were
Table 3 Final diagnoses of participants with cough and/or weight loss (n¼ 100)
Cough only
(n ¼ 28)
Cough and weight loss
(n ¼ 22)*
Weight loss only
(n ¼ 50)
Severe food insecurity — 6 14
Asthma or COPD 10 2 —
Unexplained weight loss — 2 9
Upper or lower respiratory tract infection 5 6 —
TB 2 5 5
Pulmonary 2 2 2
Extra-pulmonary — 1 2
Both — 2 1
Post-TB chronic lung disease 4 5 —
Weight loss due to loss of appetite† — 3 5
Weight loss due to depression — 2 1
Diarrhoeal illness — — 3
Malignancy‡ — — 3
Upper airway cough syndrome 2 2 —
Pertussis§ 2 — —
Weight loss due to previously undiagnosed type 2 diabetes — 1 1
End-stage renal disease — — 2
Other¶ 3 4 7
* 38 final diagnoses made for 22 participants with both cough and weight loss
†Weight loss only, n¼3: stress-related, n¼2; unexplained, n¼1; both cough and weight loss, n¼5: treatment-related, n¼3; stress-related, n
¼ 2.
‡ Newly diagnosed Hodgkin’s lymphoma, n¼1; progression in previously diagnosed malignancy (renal cell carcinoma, n¼1; cervical cancer, n¼
1).
§ One confirmed, and one likely.
¶ 1) Cough only, n¼3: GORD-related, n¼1; post-thoracic surgery for benign lung mass, n¼1; smoking-related, n¼1. 2). Weight loss only, n¼
7: endoscopy-confirmed gastritis, n¼ 1; confirmed heart failure, n¼ 1; subclinical hyperthyroidism, n¼ 1; increased exercise, n¼ 1; chronic
unexplained gastrointestinal symptoms resolving by end of study, n¼ 1; likely chronic pelvic infection, n¼ 1; hazardous alcohol intake and
weight loss after stopping, n¼ 1. 3). Both cough and weight loss, n¼ 4: ACE inhibitor-related cough, n¼ 1; post-infectious cough, n¼ 1;
weight loss likely due to recurrent small bowel obstruction, n¼ 1; weight loss due to unexplained loss of appetite, n¼ 1.
COPD¼ chronic obstructive pulmonary disease; TB¼ tuberculosis; GORD¼gastro-oesophageal reflux disease; ACE¼ angiotensin-converting
enzyme.
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infectious (TB, 46%; lower respiratory tract infec-
tion, 31%).21 Munyati et al. also identified a high
proportion of non-communicable disease diagnoses,
in particular post-tuberculous disease, asthma and
heart failure.21 We also found post-TB chronic lung
disease to be a relatively common diagnosis; better
criteria to distinguish it from active TB and optimal
management are needed.22–24 Our data support
Chakaya et al.’s call for large-scale epidemiological
studies of post-TB lung disease.22
Severe food insecurity was the most common cause
of weight loss. Food insecurity has not previously
been evaluated as a possible cause for weight loss in
the context of TB screening, although it is well
described as a barrier to adherence to ART.25We only
assigned this diagnosis after searching for other, more
likely diagnoses, and chose severe (rather than
moderate) food insecurity as a more specific marker.
Clinicians should consider screening for food insecu-
rity among people with weight loss, particularly if not
associated with other symptoms, and ensure patients
are linked to social support where available. Forty per
cent of our study participants screened positive for
significant depression, and almost one fifth had
harmful alcohol use, comparable with estimates of
31% and 7–31%, respectively, from a systematic
review in sub-Saharan Africa of HIV-positive people
on ART by Nakimuli-Mpungu et al.26 In their pooled
analysis, individuals with significant depression were
less likely to adhere to ART.26 Screening for
depression with provision of appropriate care should
be part of the HIV care package in lower-income
settings to help optimise ART adherence and treat-
ment outcomes.
The WHO tool was developed for use in resource-
limited settings to provide a simple clinical algorithm
to reliably rule out TB before providing isoniazid
preventive therapy to PLHIV. As the tool was
designed to maximise sensitivity (78.9%) and mini-
mise the negative likelihood ratio for TB, it has low
specificity (49.6%). At a TB prevalence of 5% in
PLHIV, it has a negative predictive value of 97.7%,
but a very low positive predictive value (8%).27
Individuals who screen positive, the majority of
whom will not have TB, require further evaluation
for TB using Xpert, which has been recommended as
the initial diagnostic test.1 This poses a huge
challenge in resource-constrained settings when it is
used, as recommended, for active TB case finding in
PLHIV at every clinical encounter.1 Simple, low-cost
strategies to prioritise those with WHO tool symp-
toms for TB investigation, such as ‘second-step’
clinical algorithms,15,28 or point-of-care CRP testing
(also suggested as an alternative TB screening tool),29
are potential solutions that merit further evaluation.
Strengths of our study included our systematic
physician evaluation of a representative sample of
HIV clinic attendees in a clinically relevant manner
with a standardised set of investigations and longitu-
dinal follow-up of participants. We cannot rule out
that additional diagnosis of TB and other specific
diagnoses might have been made if further investiga-
tions had been undertaken. Weight loss was com-
monly reported by our study participants, but we
restricted our study to those with measured weight
loss to make this criterion more objective.
CONCLUSIONS
TB, post-TB chronic lung disease and food insecurity
were the main diagnoses for symptoms suggestive of
TB in our population of HIV clinic attendees who had
previously undergone systematic screening and inves-
tigation for TB, and we were able to assign diagnoses
for more than 90% of participants. Our study
highlights the need to continue to investigate for TB
using multiple modalities among HIV-positive people
with persistent symptoms, as well as evaluation for
food insecurity, and for further studies to guide the
identification and management of the sequelae of
pulmonary TB.
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APPENDIX
MAIN STUDY PROCEDURES FOR XPHACTOR
Enrolment
At enrolment, research staff administered a standard-
ised questionnaire, which incorporated the World
Health Organization (WHO) tool, collected details of
tuberculosis (TB) and human immunodeficiency virus
(HIV) treatment, and basic demographic and socio-
economic information. Further investigation was
prioritised according to the XPHACTOR (‘Xpert
for people attending HIV/AIDS care: test or review?’)
algorithm with an immediate spot sputum sample
sent for Xpertw MTB/RIF (Cepheid, Sunnyvale, CA,
USA) testing for individuals at a priori highest risk of
active TB: 1) all assigned ‘high priority’ (any of the
following: current cough, fever 7 3 weeks, body
mass index [BMI] ,18.5 kg/m2, CD4 count ,
1003106/l, measured weight loss710% in preceding
6 months or other feature raising high clinical
suspicion of TB); 2) those in the pre-ART group with
CD4 count of ,2003106/l at enrolment; 3) all those
in the HIV testing and counselling (HTC) group
(whose CD4 count was unknown) at enrolment. For
all other participants, a spot sputum sample was
collected at enrolment and frozen at808C within 24
h for testing with Xpert at the end of the study (Figure
A.1). This enabled comparison of sensitivity and
specificity of the XPHACTOR study algorithm to
detect TB cases against sensitivity and specificity if
Xpert had been performed immediately for all with
any WHO tool symptom.
Follow-up
Participants were reviewed monthly to 3 months,
with repeat WHO symptom screen and a spot sputum
requested for Xpert if ‘high priority’ by the study
algorithm at that visit, with the exception of those in
the ‘on ART’ group who were asymptomatic at
enrolment, who were telephoned at 1 and 2 months
to update locator information but were not asked
about TB symptoms. At the 3-month visit, sputum
(induced if necessary) and blood were collected for
mycobacterial culture on liquid media (BACTEC
MGITe [Mycobacterium Growth Indicator Tubes;
BD, Sparks, MD, USA] 960e and 9240e systems)
from all study participants, regardless of symptoms
(Figure A.1). We allowed a broad window period
around the scheduled 3-month visit until around 6
months to maximise study follow-up.
Participants who submitted an Xpert sample were
reviewed within 1 week. If Xpert-positive, anti-
tuberculosis treatment was initiated; if negative,
research staff repeated WHO symptom screening
and facilitated the Xpert-negative algorithm, which
comprised chest radiograph (CXR), spot sputum for
TB culture and/or antibiotic trial as clinically
appropriate (Figure A.1).
Investigation results were returned to clinic staff,
who were responsible for management decisions.
Clinic records were reviewed at the end of the study
to ascertain any additional relevant investigations
and/or TB diagnoses. Deaths were identified through
reports from participant-nominated contacts, clinic
staff, and by accessing the Department of Home
Affairs vital statistics database using participants’
South African identification (ID) numbers.
Sub-study research physician assessment
The research physician administered a standardised
questionnaire which had targeted questions to
systematically identify the cause for WHO tool
symptom(s) reported. All participants were asked
about past medical history, current medications, and
investigations and treatment undertaken to date. For
example, those with cough were asked about cough
duration and triggers, associated symptoms and any
preceding respiratory tract infection. Results for all
previous investigations undertaken for the study were
reviewed by the research physician, for example,
CXR and abdominal ultrasound scan; Xpert and
mycobacterial culture on sputum; and sputum,
nasopharyngeal and oropharyngeal samples for
respiratory pathogens. Participants with pleural
effusions or lymphadenopathy were referred to the
clinic physician for consideration for aspiration or
fine-needle aspiration, as appropriate. Symptom-
specific evaluation undertaken by the research
physician is summarised below.
EVALUATION OF COUGH
First-line evaluation
Blood samples were collected from all participants
with cough for full blood count and, where appro-
priate, C-reactive protein (CRP), to help distinguish
the likelihood of bacterial respiratory infection and, if
febrile (.38.38C), aerobic and anaerobic bacterial
blood cultures. If bacterial infection was suspected,
oral antibiotics or hospital admission were facilitated
when clinically appropriate.
A trained research physician performed spirometry
in accordance with American Thoracic Society (ATS)
and European Respiratory Society (ERS) standards1
for any participant with cough7 8 weeks, or features
suggestive of chronic obstructive pulmonary disease
(COPD) or asthma, unless respiratory clinic spirom-
etry results were already available. The Advanced
Medical Engineering spirometer (AME, Cape Town,
South Africa) was used, with calibration checks
performed in accordance with the manufacturer’s
recommendations. Up to eight seated readings were
taken, and post-bronchodilator (5 mg nebulised
salbutamol) spirometry performed if a spirometry
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abnormality was found. If ATS/ERS within- and
between-manoeuvre acceptability criteria were not
met, we reported usable curves (good start and
satisfactory exhalation). Post-bronchodilator spirom-
etry data were used to confirm airflow obstruction,
defined using Global Lung Initiative (GLI) 2012
equations (forced expiratory volume in 1 s [FEV1]/
forced vital capacity [FVC], lower limit of normal at
the 5th centile).2 Post-bronchodilator increase in
FEV1 .12% of predicted and .200 ml was used to
confirm asthma. Participants were referred to the
clinic physician for further management if spirometry
confirmed asthma or COPD, or if spirometry was
normal but obstructive airways disease likely, or if
another spirometry abnormality was identified. Re-
sponse to any treatment provided was assessed at 4–
12 weeks.
If participants had clinical features suggestive of
cardiac failure, serum b-natriuretic peptide (BNP)
was measured and if levels were .100 pg/ml, further
Figure A.1 XPHACTOR main study flow and procedures. * XPHACTOR algorithm at enrolment: high priority (any of current cough,
fever7 3 weeks, BMI, 18.5 kg/m2, CD4, 1003106/l, measured weight loss7 10% in preceding 6 months or other feature raising
high clinical suspicion of TB); medium priority (any of fever ,3 weeks, night sweats, measured weight loss ,10% in preceding 6
months); low priority¼no TB symptoms. † Samples tested using Xpert at the end of the study to enable comparison of sensitivity and
specificity of the XPHACTOR study algorithm to detect TB cases against sensitivity and specificity if Xpert had been performed
immediately for all with any WHO tool symptom. ‡ XPHACTOR algorithm at monthly follow-up: high priority (any of current cough,
fever73 weeks, night sweats74 weeks, BMI, 18.5 kg/m2, CD4, 100x106/l, measured weight loss710% in preceding 6 months
or other feature raising high clinical suspicion of TB); medium priority (any of fever ,3 weeks, night sweats ,4 weeks, measured
weight loss,10% in preceding 6 months); low priority¼no TB symptoms. § Screened by research nurse between October 2013 and
April 2014. Eligible if not on anti-tuberculosis treatment and persistent or recurrent TB symptoms, defined as: 1) any of cough, fever or
night sweats reported at enrolment and any of aforementioned symptoms reported at 3-month visit; OR 2)75% measured weight
loss at 3-month visit and reported unintentional weight loss. XPHACTOR¼Xpert for people attending HIV/AIDS care: test or review?
HIV¼ human immunodeficiency virus; ART¼antiretroviral therapy; BMI¼ body mass index; TB¼ tuberculosis; WHO¼World Health
Organization.
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cardiological evaluation and management was facil-
itated. If participants had symptoms compatible with
Pneumocystis jiroveci pneumonia (fever/exertional
dyspnoea/tachypnoea) and CD4 count ,200 cells/ll,
exercise oximetry was undertaken and the participant
referred to the responsible clinic physician for further
management.
Any suspicious CXR features were discussed with
the clinic physician to facilitate further appropriate
evaluation or treatment as deemed appropriate, for
example, pleural aspiration, computed tomography
(CT) imaging, endoscopy or bronchoscopy or pre-
sumptive anti-tuberculosis treatment.
Second-line evaluation of cough
If diagnosis for cough was not identified by first-line
evaluation, a trial of appropriate treatment was
arranged for those with clinical features suggestive
of cough due to upper airways disease, angiotensin-
converting enzyme (ACE) inhibitors or gastro-
oesophageal reflux (GORD). This comprised corti-
costeroid nasal spray and/or antihistamine, or ear,
nose, throat referral if upper airways disease was
suspected; switching ACE inhibitor to a suitable
alternative; lifestyle advice and trial of a proton pump
inhibitor if GORD was suspected. Response to
treatment was reviewed at 4–12 weeks. Smoking
cessation advice was given to all current smokers, and
improvement in cough evaluated at 4–12 weeks post-
cessation, if applicable. If no likely cause for cough
was identified after second-line evaluation, referral to
a respiratory physician was facilitated.
Evaluation of75% unintentional weight loss
Evaluation aimed to identify a broad spectrum of
causes of weight loss, including TB, endocrine
Figure A.2 Evaluation for TB undertaken for all study participants. *At least one sputum for Xpert or mycobacterial culture; 11
participants had both. † Pleural effusion (n¼1). ‡ Pleural effusion (n¼5), upper lobe infiltrates (n¼4), cardiomegaly with ultrasound
confirmed pericardial effusion and pleural effusion (n ¼ 1), cardiomegaly with ultrasound confirmed pericardial effusion (n ¼ 1)
cavitation and pleural effusion (n ¼ 1). § Three of the four participants with M. tuberculosis on sputum culture had previously had
sputum negative for M. tuberculosis on culture and/or Xpert before sub-study enrolment. ¶ Participant had previously had negative
sputum for mycobacterial culture at enrolment to sub-study. CXR¼ chest radiograph; TB¼ tuberculosis.
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Table A Criteria for diagnoses assigned for WHO tool symptoms
Diagnosis Criteria
Cough
Asthma Likely: compatible symptoms (recurrent or chronic cough,* wheeze, dyspnoea, chest tightness)
without spirometry confirmation;
Confirmed: compatible symptoms confirmed using spirometry (GLI criteria,† and improvement in
FEV1 after bronchodilator, .12% predicted and .200 ml); OR documented diagnosis
COPD Age .35 years and risk factor (smoking or snuff use or exposure to biomass fuel); AND
Likely: compatible symptoms (chronic cough,* wheeze, dyspnoea, sputum production, frequent
bronchitis) and either borderline FEV1/FVC on spirometry or absence of spirometry confirmation
Confirmed: compatible symptoms confirmed using spirometry;† OR documented diagnosis
Not COPD: compatible features but normal spirometry
Post-TB CLD Post-TB bronchiectasis: chronic* productive cough with compatible chest CT scan; OR documented
diagnosis
Chronic loculated pleural effusion post-TB: documented diagnosis with compatible chest
ultrasound or CT scan
Likely post-TB CLD: chronic cough* or recurrent respiratory tract infections‡ in patient previously
treated for TB, and/or CXR abnormality compatible with previous pulmonary TB (fibrosis,
hyperinflation, bronchovascular distortion, bronchiectasis)
Lower respiratory tract infection Symptoms for 63 week duration, and:
Cough and 71 lower respiratory tract symptom (fever, sputum production, breathlessness,
wheeze, chest discomfort or pain)
Upper respiratory tract infection Symptoms for 63 weeks’ duration, and includes:
Cold: 71 of cough, nasal symptoms, sneezing, sore throat;
Influenza: fever and 71 of headache, myalgia, cough or sore throat
Pertussis Acute cough 72 weeks and symptomatic (71 of: paroxysms of cough, post-tussive vomiting or
inspiratory whoop)
Likely: no microbiological confirmation and no other likely cause
Confirmed: respiratory sample positive for Bordetella pertussis
Post-infectious cough Cough duration 3–8 weeks preceded by acute respiratory tract infection and no other likely cause
Gastro-oesophageal reflux disease Compatible symptoms (chronic cough worse with or after meals associated with heartburn or
regurgitation, dysphonia, cough resolves during sleep) improving within 3 months with
appropriate treatment
Upper airway cough syndrome Chronic* or recurrent cough and compatible symptoms (post-nasal drip, nasal discharge or
congestion, catarrh) responding to appropriate treatment; OR documented diagnosis
Likely: symptoms as above but no trial of treatment, and no other likely cause
ACE inhibitor cough Chronic* dry cough resolving within 12 weeks of stopping ACE
Tobacco-related cough Current smoker or snuff user and no other likely cause for cough
Unintentional weight loss
Malignancy Compatible clinical features with confirmatory imaging or histology; OR documented diagnosis
Food insecurity Compatible HFIAS score (severe food insecurity)
Type 2 diabetes HbA1c 7 48 mmol/mol (6.5%) and compatible symptoms
Hyperthyroidism Low TSH with raised free thyroxine level
Subclinical/biochemical: low TSH with normal free thyroxine level
Depression Compatible history and PHQ-9 score 710; OR documented diagnosis
Stress-related History of loss of appetite triggered by acute stressful event
Treatment-related History of loss of appetite/reduced food intake due to side effects of medical treatment (e.g., switch
to second-line ART)
Fever/night sweats
Infection Likely: compatible symptoms responding to appropriate treatment or resolving spontaneously
Confirmed: compatible symptoms with microbiological confirmation
Perimenopause Compatible symptoms, confirmed with FSH if age ,45 years, and no other likely cause
Diagnoses relevant to .1 WHO tool symptom
Confirmed TB Positive result on 1) Xpert or 2) line-probe assay or 3) M. tuberculosis culture, from any sample
collected within 6 months of sub-study enrolment
Clinical TB Anti-tuberculosis treatment started within 6 months of sub-study enrolment in the absence of
microbiological confirmation
Heart failure§ Likely: compatible symptoms (orthopnoea, dyspnoea, peripheral oedema) and serum BNP. 100 pg/
ml
Confirmed: compatible symptoms and echocardiogram; OR documented diagnosis
Alcohol misuse¶ Hazardous alcohol consumption (FAST score 73) and no other likely cause
Unexplained, symptom resolved
spontaneously
No cause for symptom identified, and symptoms resolved by final study visit
Unexplained No cause identified
*Defined as cough 78 weeks.
† Defined as no improvement in FEV1 after bronchodilator and either 1) GLI
2 equation criterion FEV1/FVC ,lower limit of normal, or 2) GOLD FEV1/FVC , 0.7.
GOLD criteria were used in spirometry results from medical records.
‡ Defined as 72 episodes in preceding 6 months.
§ Considered as possible cause of chronic cough or weight loss.
¶ Considered as possible cause of weight loss or sweats on withdrawal.
WHO¼World Health Organization; GLI¼Global Lung Initiative; FEV1¼ forced expiratory volume in 1 s; COPD¼Chronic Obstructive Lung Disease; FVC¼ forced
vital capacity; TB¼ tuberculosis; CLD¼chronic lung disease; CT¼computed tomography; CXR¼chest radiograph; ACE¼angiotensin-converting enzyme; HFIAS¼
Household Food Insecurity Access Score; HbA1c¼ glycated haemoglobin; TSH ¼ thyroid stimulating hormone; PHQ9 ¼ Patient Health Questionnaire 9; ART ¼
antiretroviral therapy; FSH¼ follicle stimulating hormone; BNP¼brain natriuretic peptide; FAST¼Fast Alcohol Screening Test; GOLD¼Global Initiative for Chronic
Obstructive Lung Disease.
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disorders, malignancy, depression, inadequate access
to food and drug misuse.
Blood samples were collected from all participants
with weight loss for renal, liver and thyroid function,
full blood count and glycated haemoglobin (HbA1c;
to identify type 2 diabetes mellitus), and clinically
significant results were reported to the clinic physi-
cian for further management. If participants reported
diarrhoea, stool samples were collected for micros-
copy, bacterial culture, parasitology and for Clostrid-
ium difficile, if antibiotics had been taken in the
preceding 12 weeks.
The Patient Health Questionnaire-9 (PHQ-9)3 was
used to screen all sub-study participants for depres-
sion. This score categorises depression as 0–4 (none
or minimal), 5–9 (mild), 10–14 (moderate), 15–19
(moderately severe) and 20–27 (severe). Participants
with scores of 710 were evaluated further by the
research physician, and referred to the clinic physi-
cian or psychology service if deemed clinically
depressed. The Fast Alcohol Screening Test (FAST)4
was used to screen for hazardous alcohol consump-
tion (FAST score7 3) and all participants were asked
about drug misuse. If FAST score was 73, brief
intervention was provided and, if appropriate,
participants were referred to drug services.
We used the Household Food Insecurity Access
Scale (HFIAS)5 to measure food access, categorising
the scale as 1) ‘food secure’, 2) ‘mildly food insecure
access’, 3) ‘moderately food insecure access’ or 4)
‘severely food insecure access’. A HFIAS score of 4
was deemed a cause of unintentional weight loss.
Participants with food insecurity were referred to the
clinic dietician.
Clinical features suggestive of possible malignancy
were discussed with the clinic physician to facilitate
further appropriate evaluation or treatment as
deemed appropriate.
Evaluation of fever or night sweats
Self-recorded participant temperature measurements
were reviewed. If a likely focus of infection was
identified, then relevant samples were submitted for
appropriate microbiological evaluation such as mid-
stream urine (bacterial culture), stool (bacterial
culture, parasitology, Clostridium difficile), sputum
(bacterial culture), blood (malaria film) or swabs
(bacterial culture). If deemed clinically appropriate,
antibiotics were provided and the participant re-
viewed to assess response to treatment.
If no likely focus infection was identified, blood
was collected for renal, liver and thyroid function,
full blood count, CRP, HbA1c, aerobic and anaerobic
culture if documented fever .38.38C; and urine for
microscopy and culture. Abdominal ultrasound was
arranged and CXR, if either no recent film or no film
since onset of symptoms.
A clinical diagnosis was made if no other more
likely cause was identified, and symptoms were
suggestive of perimenopausal vasomotor symptoms
in females aged 745 years; in younger cases, blood
samples were collected to determine follicle-stimulat-
ing hormone (FSH) levels.
If, during in-patient treatment, specialist referral or
further evaluation such as lumbar puncture, CT
imaging (abdomen, chest, sinus), fine-needle aspira-
tion, bone-marrow aspiration or pleural aspiration
were deemed necessary, this was facilitated by the
clinic physician.
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R E´ S U M E´
O B J E C T I F : Identifier les causes des symptoˆmes
suggestifs de tuberculose (TB) parmi les personnes
vivant avec le virus de l’immunode´ficience humaine
(PVVIH) en Afrique du Sud.
M E´ THODE : Un e´chantillon conse´cutif de patients d’un
dispensaire VIH ayant des symptoˆmes suggestifs de TB
(71 parmi toux, perte de poids, fie`vre ou sueurs
nocturnes) lors de l’enroˆlement et a` 3 mois, mais des
premie`res investigations a` la recherche de TB ne´gatives,
a e´te´ syste´matiquement e´value´ graˆce a` des protocoles
standard et des diagnostics assigne´s graˆce aux crite`res
standard. La TB a e´te´ « confirme´e » lorsque
Mycobacterium tuberculosis a e´te´ identifie´ dans les 6
mois de l’enroˆlement, et « clinique » si le traitement a
de´marre´ sans confirmation microbiologique.
R E´ S U LTAT S : Parmi 103 participants, 50/103 pre´ ART
et 53/103 sous ART, respectivement ; 68% contre 79%
ont e´te´ des femmes ; d’aˆge me´dian 35 contre 45 ans, et le
taux me´dian de CD4 de 311 contre 508 cellules/mm3.
Soixante-douze patients (70%) ont eu une perte de poids
mesure´e 75% et 50 (49%) une toux. Les diagnostics
finaux les plus fre´quents ont e´te´ une perte de poids due a`
une inse´curite´ alimentaire majeure (n ¼ 20, 19%), une
TB (n ¼ 14, 14% : confirme´e, n ¼ 7 ; clinique, n ¼ 7),
d’autres infections des voies respiratoires (n¼14, 14%),
une affection pulmonaire post-TB (n¼ 9, 9%). La base
du diagnostic de TB a e´te´ l’imagerie (n ¼ 7), la
confirmation bacte´riologique des crachats (n ¼ 4),
l’histologie, la ponction lombaire et autres (n ¼ 1
chacun).
CONC LU S I ON : Les PVVIH ayant des symptoˆmes de
TB persistants requie`rent davantage d’e´valuation a` la
recherche de TB avec toutes les modalite´s disponibles et
a` la recherche de proble`mes de se´curite´ alimentaire chez
ceux qui ont perdu du poids.
R E S UM E N
MARCO DE R E F E R ENC I A: El estudio tuvo por objeto
reconocer las causas de los sı´ntomas indicativos de
tuberculosis (TB) en las personas infectadas por el virus
de la inmunodeficiencia humana (PLVIH) en Sura´frica.
M E´ TODO: Una muestra consecutiva de pacientes que
acudı´an a la consulta del VIH y presentaban sı´ntomas
indicativos de TB (uno o varios sı´ntomas como tos,
pe´rdida de peso, fiebre o sudoracio´n nocturna) en el
momento de la inscripcio´n y a los 3 meses y cuyas
investigaciones iniciales de la TB habı´an sido negativas
se evaluo´ de manera sistema´tica mediante protocolos
normalizados y los diagno´sticos se asignaron segu´n
criterios definidos. El diagno´stico de TB se considero´
‘confirmado’ cuando se detectaba el Mycobacterium
tuberculosis en los primeros 6 meses despue´s de la
inscripcio´n en la consulta y ‘clı´nico’ cuando se iniciaba
tratamiento sin confirmacio´n microbiolo´gica.
R E SU LTADOS: De los 103 participantes, 50 no recibı´an
aun tratamiento antirretrovı´rico y 53 ya lo recibı´an;
respectivamente, el 68% y el 79% eran de sexo
femenino, la mediana de la edad era 35 y 45 an˜os; la
mediana de la cifra de linfocitos CD4 fue 311 y 508
ce´lulas/mm3. Setenta y dos pacientes (70%) presentaron
una pe´rdida de peso cuantificada75% y 50 presentaron
tos (49%). Los diagno´sticos definitivos ma´s frecuentes
fueron pe´rdida de peso debida a una inseguridad
alimentaria grave en pacientes (n ¼ 20, 19%), TB (n ¼
14, 14%: 7 diagno´sticos confirmados y 7 clı´nicos), otras
infecciones de las vı´as respiratorias (n ¼ 14, 14%) y
enfermedad pulmonar cro´nica posterior a la TB (n¼ 9,
9%). El diagno´stico de TB se fundamento´ en las
ima´genes (n ¼ 7), la confirmacio´n bacteriolo´gica en el
esputo (n¼4), el examen histolo´gico, la puncio´n lumbar
y otros medios (n¼ 1, en cada caso).
CONC LU S I O´ N: Es necesario investigar la presencia de
TB en las PLVIH y sı´ntomas persistentes indicativos de
TB, mediante todos los medios al alcance y la
inseguridad alimentaria en las personas que presentan
pe´rdida de peso.
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